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390Objective: There is a need for fast, minimally invasive sutureless replacement of mitral valves.
Methods: Unchanged FDA-approved biological valve prostheses were sutured to Nitinol attachment rings (Endo-
smart, Stutensee,Germany) thatwere coveredwith textile (devices). The lower flange of the devicewas stretched in
icewater andmaintained in a stretched positionwith stretching sutures. In 9 acute pig experiments through a limited
left thoracotomy, a single suturewas placed around themitral annulus, the devicewas positioned, the annular suture
tied, the stretching sutures retracted, and the device activated bywarm saline. Position of the device, heart and valve
function, coronary arteries, left ventricular outflow tract, and surrounding structures were observed with transoe-
sophageal echocardiography, left ventricular and coronary angiograms, and pathologic examination at autopsy.
Results: The devices could be easily navigated to the mitral valve annulus and actuated within seconds. Three
devices were placed with warm blood in the operative field and were tilted or dislocated at autopsy. In the other
6 devices, transesophageal echocardiography and left ventricular and coronary angiography demonstrated normal
prosthetic valve and heart function, without valvular or para-device leakage, andwith normal aortic valve and cor-
onary arteries. At autopsy in these 6 cases, the devices were strongly fixed at the anatomic mitral valve annulus,
without abnormalities of the device, heart valve prosthesis, left ventricular outflow tract, or aortic valve ostium.
Conclusions: Nitinol attachments rings combined with unchanged biological valve prostheses can make fast
and strong sutureless replacement of the mitral valve feasible in acute pig experiments. Applicators that con-
strain and release the device mechanically need to be developed. (J Thorac Cardiovasc Surg 2011;142:390-5)Supplemental material is available online.
Video clip is available online.
Hand suturing is the current standard of attaching a mitral
valve prosthesis to the anatomic mitral valve annulus. How-
ever, this method consumes relatively a great deal of time,
particularly in multivalve and combined procedures, and
makes minimally invasive valve surgery less favorable.
Currently, there is renewed interest in sutureless valve im-
plantations, mostly by mounting a biological aortic valve
into a metal stent and compressing it into a catheter
sleeve.1,2 However, with this technique the diseased valvee Department of Cardio-thoracic Surgery,a Catharina Hospital, Eindhoven,
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The Journal of Thoracic and Cardiovascular Surgis not removed, and current valved stents do not result in
outcomes comparable with surgically removed and
replaced heart valves.3 So far, there have been no reports
about the clinical use of primary mitral valved stents, but
there have been a few reports about their experimental
use.4-6 Previously, we7 have shown that it is feasible to
use Nitinol attachment rings to attach mechanical aortic
valve prostheses solidly to the aortic valve annulus after re-
moval of the original aortic valve in acute pig studies; we
observed that such rings can withstand a high pulling force.
Recently, we8 found that these valved rings remained well
fixed and without leakage in the aortic position in pigs dur-
ing more than 90 days of follow-up. With this study
we wanted to test the feasibility of similar sutureless
Nitinol rings to attach unchanged Food and Drug Adminis-
tration (FDA)–approved biological valve prostheses at the
anatomic mitral valve annulus. Because proven long-term
durability is an important feature of most available FDA-
approved biological valve prostheses, our intention was
not to design a complete new heart valve prosthesis but
just to provide a new sutureless implantation method.
MATERIALS AND METHODS
Devices and Applicator
After extensive in vitro testing, a mitral valve attachment ring (MVAR)
was manufactured from Nitinol memory metal (Endosmart GmbH, Stuten-
see, Germany) and covered with vascular graft textile (knitted fabric 100%
polyester; Jotec GmbH, Hechingen, Germany). This proprietary ring wasery c August 2011
Abbreviations and Acronyms
ASD ¼ atrial septal defect
FDA ¼ Food and Drug Administration
LV ¼ left ventricular
LVOT ¼ left ventricular outflow tract
MVAR ¼ mitral valve attachment ring
TEE ¼ transesophageal echocardiography
Berreklouw et al Evolving Technology/Basic Sciencegiven a slightly sinusoidal shape to match the upside of a Perimount biolog-
ical valve prosthesis (Edwards Lifesciences, Inc, Irvine, Calif) and pos-
sessed a fixed upper and flexible lower flange. The unchanged FDA-
approved valve prosthesis (7 times a reversed 23-mm aortic prosthesis
and 2 times a 25-mm mitral valve prosthesis) was placed on top and
through the MVAR, and the textile of both devices was fixed together
with a running nonresorbable polypropylene suture (4–0 Prolene; Ethicon,
Inc, Somerville, NJ) (Figure 1, A and B). An applicator was manufactured
from stainless steel, with a flexible Nitinol handle (Pierre Janssen, Instru-
mentation Department Catharina Hospital, Eindhoven, The Netherlands).
The MVAR with valve prosthesis (device) was loaded on the applicator
with 3 temporary fixing sutures. The lower flange of the MVAR was com-
posed of separate fingers that were temporary stretched manually in iced
saline to facilitate passage of the device through the mitral valve annulus.
To prevent unintended early expansion of the stretched lower flange during
navigation, we applied 3 temporary stretching sutures through the textile of
the lower flange, led them through the valve, and fixed them to the applica-
tor. The applicator loaded with the device remained in iced saline until its
use (Figure E1). Once the device was in place at its desired position at the
mitral valve annulus, it was activated by being flushed with warm (about
45C) saline from a syringe. During activation the annulus was clamped be-
tween the expanding lower flange and fixed upper flange (Video 1). Similar
rings were combined with unchanged FDA-approved mechanical mitral
valve prostheses (St Jude Medical Inc, St Paul, Minn) and successfully
tested in in vitro pig hearts in the mitral position (Video 2), but is was de-
cided to proceed first with the combined biological valved device, because
in future long-term testing no or limited anticoagulation was preferred to
enhance the likelihood of late animal survival.
Surgical Procedures and Investigations
At the start of the surgical procedure, the valve prosthesis was hand
sewn to the MVAR. The device was loaded on the applicator, manually
stretched in iced saline, and the lower flange temporarily kept in a stretchedFIGURE 1. A, Mitral valve attachment ring (MVAR) with biological valve pro
prosthesis (device) from below, left ventricular side.
The Journal of Thoracic and Caposition by stretching sutures. In 9 anesthetized and ventilated female Ger-
man Saddleback pigs (weighing between 61 and 74 kg), a limited left-sided
thoracotomy was performed through the fourth or fifth intercostal space.
One rib was partially removed, and more ribs were mobilized if needed.
The pericardium was opened longitudinally and retracted. After heparin-
ization, the animal was placed on full bypass with arterial cannulation in
the descending aorta (63), right femoral artery (23), or left carotid artery
(13). Venous cannulation was done through the right atrial appendage. A
needle was placed into the ascending aorta, the aorta was crossclamped,
and cold crystalloid (13) or blood cardioplegic (63) solution was admin-
istered. In the first and third case, therewas a deviation from the protocol by
fibrillating the heart with rapid pacing. The lateral wall of the left atrium
was opened longitudinally and retracted by a retractor. The mitral valve
in a pig, as approached from the left side, showed to be more in a more ver-
tical plane and more clockwise rotated than in humans, as approached from
the right side, with for the surgeon the posterior leaflet on the left and the
anterior leaflet on the right. In the first 3 cases the mitral valve leaflets were
left intact. In the last 6 cases the anterior mitral leaflet and its attaching
chordae were resected. A 2–0 running nonresorbable polyester 2–0 suture
(Topline PH26; HP Medica GmbH, Augsburg, Germany) was placed
around mitral annulus, with a small felt patch at the start and end of the su-
ture. This was done not only because the annular tissue in these young and
healthy pigs was very flexible, but also because only one size MVAR pro-
totype was available. In 2 cases the device needed to be repositioned. In the
first 5 cases no guiding wires were used or left behind. In the last 4 cases, 1
or 2 guiding sutures were used between the mitral valve annulus and the
upper flange of the device, which were tied after activation of the device
in only 1 case. In all other cases in which guiding wires were used, those
were removed after activation. The applicator loaded with the device was
navigated to the mitral valve annulus, and after inspection of its correct po-
sition, the annular suture was pulled and tied, and the 3 temporary stretch-
ing sutures were cut and retracted (Figure E2, A). Warm (45C) saline was
flushed over the device with a 30-mL syringe. This was done twice, al-
though one time seemed to be appropriate too (Figure E2, B). After the po-
sition of the device and the good function of the valve blades had been
checked, in the last 4 cases a left ventricular (LV) vent was left behind
through the valve for LV decompression and de-airing. The left atrium
was closed with 2 layers of running 4–0 Prolene polypropylene sutures
over felt strips (C. R. Bard, Inc, Covington, Ga), and the aortic crossclamp
was removed. The heart was defibrillated as necessary (Video 3). After ad-
equate reperfusion the left vent was removed. A summary of the surgical
procedures is given in Table 1. Inotropics and antiarrhythmic drugs were
given as needed, the animal was weaned from the extracorporeal circula-
tion, and the calculated dose of protaminewas given. Heart and valve func-
tion were evaluated and registered by transesophageal echocardiography
with Doppler (TEE) before bypass, before weaning off bypass, and aftersthesis (device) from above, left atrial side. B, MVARwith biological valve
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TABLE 1. Procedures
Case no. Arterial canulation
Cardiac
protection
AML
removed
Annular
suture
Guiding
suture
Guiding
suture tied Heart harvesting
1 Desc aorta VF* No Yes No No Thoracotomy
2 Desc aorta CC No Yes No No Thoracotomy
3 Femoral art VF* No Yes No No Thoracotomy
4 Femoral art BC Yes Yes No No Sternotomy
5 Carotid art BC Yes Yes No No Sternotomy
6 Desc aorta BC Yes Yes 1 Yes Sternotomy
7 Desc aorta BC Yes Yes 2 No Sternotomy
8 Desc aorta BC Yes Yes 2 No Sternotomy
9 Desc aorta BC Yes Yes 2 No Sternotomy
VF, Ventricular fibrillation; CC, cold crystalloid cardioplegia; BC, cold blood cardioplegia; desc, descending; art, artery; AML, anterior mitral valve leaflet; LV, left ventricle.
*Deviation from protocol; operated on fibrillating heart.
Evolving Technology/Basic Science Berreklouw et al
E
T
/B
Sbypass. After bypass, the animal was kept alive for another 2 to 3 hours. In
this time, and/or during reperfusion, an LVangiogramwas done through the
right femoral artery, and any mitral valve regurgitation was graded to be
absent or, if existent, from 1þto 4þ.9 A nonselective supravalvular coronary
angiogram was done to exclude any damage to the coronary arteries or aor-
tic valve. All angiograms were evaluated by an independent cardiologist
(Yaroslava Dmitrieva, MD), who has not been involved in the operative
procedures. After this time, each animal was humanely killed, and the heart
was taken out for gross pathologic examination. In the first 3 cases, the
heart was harvested through the limited left-sided thoracotomy and, in
the last 6 cases, through a separate sternotomy. At gross pathologic exam-
ination, position and function of the device were determined. Paravalvular
leakage was sought for with 1-mm probes. Inspection for damage of sur-
rounding structures included inspection of the LV outflow tract (LVOT)
and aortic valve ostium. Pictures were taken from all specimens. All exper-
iments were approved and performed along the Animal Research Ethics
regulations of the institution and country where the experiments took place.
In all experiments the animals received care in compliance with the Euro-
pean Convention on Animal Care and the Guide for the Care and Use of
Laboratory Animals as published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996).RESULTS
In all cases the device could be navigated quite easily to
the mitral valve annulus, and activation by heating did occur
within a few seconds. Once in the right position at the annu-
lus, the device attached itself solidly. Therewere 2 instances
in which there was a deviation from the operative protocol.
In the first case the procedure was intentionally performed
on a fibrillating heart. In that case the device showed a ten-
dency to expand too early, owing to contact with warm
blood. It was necessary to reposition the device, and finally
its suboptimal and tilted position was wrongly accepted. In
the third case, severe bleeding at the aortic needle hole did
occur, and the operation was continued with a fibrillating
heart. In the eighth case, a large atrial septal defect (ASD)
was encountered, which was primarily closed with a single
layer of large-bite suture, resulting in difficulties to attach
the device at its lowest point at the mid-posterior side of
the distorted annulus. In the other 6 cases, in which cold car-
dioplegic arrest was used and a dry operative field was ob-
tained, there were no difficulties to navigate, position, and392 The Journal of Thoracic and Cardiovascular Surgactivate the device at the mitral annulus. Although it was
difficult to retract some of the temporary stretching sutures,
in all cases the activation with warm saline was instant, and
this did not hinder the full expansion of the device and re-
moval of the applicator. In all cases done under cardioplegic
arrest and with a dry operative field, the position of the de-
vicewas verified by the surgeon to be at the right place at the
mitral valve annulus. In 8 cases the animals could be
weaned off the extracorporeal circulation (ECC). In the 6
cases in which the aorta was crossclamped, and excluding
the ASD case, the average crossclamp time was 29.8 min-
utes. The navigation of the device and its activation took
less than about 1 minute. The rest of the crossclamp time
was consumed by taking out the anterior mitral leaflet, plac-
ing the annular suture, checking the correct position of the
device, placing the LV vent, and closing the atrial wall with
a double-layered suture over Teflon strips. In the second
case, there was a long period of low cardiac output, most
likely owing to air embolism. In the third case, the arterial
cannula in the groin was accidentally removed early during
the operation and needed to be reinserted in the ascending
aorta, during which the animal sustained a period of shock.
The animal could be weaned off the ECC but died within
a half hour thereafter. In 8 cases a TEE was obtained that
showed normal function of the valve prosthesis in 6, without
any important mitral valve regurgitation, para-device leak-
age, or LVOT obstruction (Figure 2, A and B). The average
mean gradient over the valve was 3.4 mm Hg, with an aver-
age maximum gradient of 6.9 mm Hg. In the first case that
was done under ventricular fibrillation a 2þ regurgitation
was seen, whereas in the eighth casewith an ASD the device
was seen in the left atrium. LV (Figure 3, A and B) and cor-
onary angiography, as done in 5 cases, demonstrated the po-
sition of the device at the mitral valve annulus in all, without
any mitral valve regurgitation, para-device leakage, and
with normal LVOT and coronary anatomy. At autopsy, in
all the cases in which cold cardioplegic arrest was used,
with the exception of the ASD case, the device proved to
be solidly fixed to the anatomic mitral valve annulus,ery c August 2011
FIGURE 2. Device in mitral position at diastole (A) and systole (B) on transesophageal echocardiography.
Berreklouw et al Evolving Technology/Basic Sciencewithout any para-device leakage, with normal prosthetic
valve function, and no damage to the surrounding tissues,
including a widely patent LVOT and aortic valve ostium
(Figure 4, A and B; Video 4). In the first case the device
was found tilted at the posterior side, as was seen during im-
plantation. In the third case the device was found to be mi-
grated in the left atrium. In both cases there had been
a deviation from the protocol, working in awarm fibrillating
heart, that led to a too early expansion of the lower flange. In
the eighth case the device was found to be migrated in the
left atrium and the ASD was found to have reopened again.
The outcome of the experiments is summarized in Table 2.
COMMENT
Although our experience with the use of Nitinol attach-
ment rings to attach unchanged FDA-approved biological
valve prostheses suturelessly to the mitral valve annulus is
still very limited, we demonstrated that it is potentially fea-
sible to replace the mitral valve with such a device in an ar-
rested heart, without any para-device or valvular leakage,
low valve gradients, and no damage to the surrounding
structures. At autopsy, in the first case a tilted position
and in the third and eighth cases a luxated position of the de-
vice were found. In 2 of these cases there had been a devia-FIGURE 3. Device in mitral position at diastole (A
The Journal of Thoracic and Cation from the study protocol by trying to implant the device
in a warm fibrillating heart. Not only should we have stuck
to the protocol, but the imperfect position should not have
been accepted by the surgeon. That the TEE and LVangio-
gram before the animals were humanely killed did not show
any regurgitation in the first and third cases can be ex-
plained by the original mitral valve being intact. In the
eighth case the anatomy of the mitral annulus had been dis-
torted after closure of a large ASD. Also in this case the op-
erative field was hindered by warm blood. In all 3 cases the
stretching sutures could not prevent early expansion of the
lower flange after contact with the warm heart and blood.
A stronger mechanical way of constraining the lower flange
may prevent such early expansion of the lower flange and
could make use of the device in a warm beating or fibrillat-
ing heart possible. One can argue that placing a valve pros-
thesis on top and through an intra-annular attachment ring
can potentially diminish its effective orifice. Our TEE ex-
aminations, however, did show low prosthetic valve gradi-
ents. The thickness of the metal ring itself is less than 1
mm, and the thickness of the textile cloth can be further di-
minished. The prosthetic valves that were used were not
specifically manufactured for the rings; it can be foreseen
that in the final product the ring and valve will be) and systole (B) on left ventricular angiogram.
rdiovascular Surgery c Volume 142, Number 2 393
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FIGURE 4. Device in mitral position from left atrial side (A) and left ventricular side (B) at autopsy.
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also in respect to the distance that the valve prosthesis is po-
sitioned inward the left atrium, and to the shape and thick-
ness of the valve struts. Placement of the valve prosthesis on
top (supra-annular) of the attachment ring means that it is
positioned higher inside the left atrium, resulting in a lower
risk for LVOT obstruction, as can sometimes be observed
with biological prostheses that are hand sewn.10 One can
also argue that use of a single annular suture means that
the method is in fact not fully sutureless. However, such su-
ture is not connected directly to the device. Also, Magovern
and associates11,12 used such a single annular suture in
many of the clinical cases of aortic or mitral valve
replacement with the Magovern sutureless prosthetic
valve. It is not clear yet whether such suture will be
necessary in the human situation, where the mitral valve
annulus will be more pathologically degenerated and rigid
by calcifications, than in the young and healthy pigs we
used in these acute experiments. It is also conceivable to
stiffen and/or narrow the natural valve annulus with other
sutureless methods in the future.
The current still experimental mitral valved stents4-6 have
more difficulty with attaching themselves solidly to theTABLE 2. Outcome
Case no. Weaned from ECC MR LV angio/TEE
1* Yes 2+
2 No 0
3* Yes 0
4 Yes 0
5 Yes 0
6 Yes —
7 Yes 0
8y Yes 4+
9 Yes 0
ECC, Extracorporeal circulation; MR, mitral regurgitation; TEE, transesophageal echoc
*Operated on fibrillating heart. yLarge atrial septal defect; device malpositioned.
394 The Journal of Thoracic and Cardiovascular Surgmitral valve annulus and still have a relatively higher risk
for paravalvular leakage. The difference between a valved
stent and our Nitinol ring is that the valved stent loses its
radial expansion force as soon as the valve prosthesis
inside the stent has fully expanded, whereas the force
between the flanges of our Nitinol ring will remain active,
independent of the grade of expansion of the valve
prosthesis. Another disadvantage of valved stents is that
because they need their radial expansion to attach, in the
often dilated mitral valve annulus, very large stent
diameters with large valve diameters will be required.
Expansion of such dilated annulus by a valved stent may
compress the LVOT and distort the aortic valve ostium, or
the lower side of the stent may cause LVOT obstruction.
All these theoretical disadvantages may be prevented by
using Nitinol rings, which have a fixed diameter, have
a relatively short height, and use axial compression. It is
foreseeable in the future that our devices can be crimped
similar to valved stents, but that they will attach
themselves with a stronger adhesive force than that of
(current) valved stents. We are currently developing an
applicator that can hold and constrain the device
mechanically, preventing early expansion of the lowerLVOTO LV angio/TEE Device at autopsy
0 Tilted
0 Good position, no leakage
0 Dislocated
0 Good position, no leakage
0 Good position, no leakage
— Good position, no leakage
0 Good position, no leakage
0 Dislocated
0 Good position, no leakage
ardiography; LV, left ventricle; LVOTO, left ventricular outflow tract obstruction.
ery c August 2011
Berreklouw et al Evolving Technology/Basic Scienceflange when in contact with warm blood, and allowing its
use in a fibrillating or beating heart too. Further long-term
animal testing will be necessary to prove the feasibility of
this method to replace the mitral valve suturelessly.
Some parts of the prototypes were provided by Edwards Life-
sciences, Ltd (Irvine, Calif), Endosmart GmbH (Stutensee, Ger-
many), Jotec GmbH (Hechingen, Germany), and St Jude
Medical, Inc, St Paul, Minn. The videos were produced by Media-
ventures, Merelbeke, Belgium.
Besides the authors, the following persons contributed to the
Acute Sutureless Mitral Valve Project (in alphabetical order): Yar-
oslava Dmitrieva, MD (cardiologist, Herzzentrum Leipzig,
Germany), Grit Gerullis (veterinarian assistant, Herzzentrum Leip-
zig, Germany), Yme Groeneveld (EPS, The Hague, Netherlands),
Olliver Gross (perfusionist, Herzzentrum Leipzig, Germany), Joc-
henHahn,MD(surgical assistant, HerzzentrumLeipzig,Germany),
Pierre Janssen (Instrumentation Department Catharina Hospital,
Netherlands), Willem-Jan Janssen (Edwards Lifesciences, Nether-
lands), Astrid Jorna (St Jude, Netherlands), Henk van Kemenade
(Van Kemenade Slaughterhouse, Netherlands), Sara Klein (veteri-
narian assistant, Herzzentrum Leipzig, Germany), Marjan van
Marle (traffic, Netherlands), Hardy Mueller (Jotec GmbH,
Germany), Thomas Mueller (perfusionist Herzzentrum Leipzig,
Germany), StevenNoulet (Mediaventures, Belgium),MikeRoelofs
(Audiovisual Department, Catharina Hospital, Netherlands), Carl
Swindle (Edwards Lifesciences, Irvine, Calif), Guy van Dael
(Audiovisual Department Catharina Hospital, Netherlands), Wim
Van Renterghem (Mediaventures, Belgium), and Veid Zebralla
MD (surgical assistant Herzzentrum Leipzig, Germany).The Journal of Thoracic and CaReferences
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FIGURE E1. Device loaded and stretched on applicator in ice water.
FIGURE E2. A, Device and applicator positioned in mitral valve annulus before activation. B, Device positioned in mitral valve annulus after activation.
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